Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use
- PMID: 33800965
- PMCID: PMC8003881
- DOI: 10.3390/jcm10061289
Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use
Abstract
Dry eye disease is a common ocular condition affecting millions of people worldwide. Artificial tears are the first line therapy for the management of dry eye disease. Artificial tear formulations contain a variety of active ingredients, biologically active excipients, and preservatives. Many of these formulations are also available as preservative-free. This study was conducted to inspect artificial tear formulations currently marketed in the United States for their active ingredients, biologically relevant excipients, and preservatives. The marketed artificial tears were examined at various US retail pharmacy chains and using the manufacturers' website to compile information about active ingredients, inactive ingredients, and preservatives. The currently marketed artificial tears can be grouped into four categories based on their active ingredients. The artificial tears also contain biologically active chemicals listed as inactive ingredients, which have osmoprotectant, humectant, and tear film lipid layer or mucous layer mimicking properties. Most artificial tears contain vanishing type preservatives such as purite or sodium perborate and safer quaternary compound polyquaternium-1. The majority of these artificial tear formulations are also available as preservative-free single dose unit. The study provides a formulary of artificial tears based on active ingredients, biologically active excipients, and the preservative-free option. The formulary should assist healthcare providers in making a stepwise and rational selection of appropriate artificial tears for patients suffering from dry eye disease.
Keywords: artificial tears; demulcents; dry eye; humectants; ophthalmic preservatives; osmoprotectants.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations.Int J Mol Sci. 2023 Feb 1;24(3):2758. doi: 10.3390/ijms24032758. Int J Mol Sci. 2023. PMID: 36769079 Free PMC article. Review.
-
Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.Int J Mol Sci. 2022 Feb 23;23(5):2434. doi: 10.3390/ijms23052434. Int J Mol Sci. 2022. PMID: 35269576 Free PMC article. Review.
-
Relative costs of various preserved artificial tear solutions for the treatment of dry eye conditions.Eye Contact Lens. 2003 Oct;29(4):238-40. doi: 10.1097/01.icl.0000090882.94633.1C. Eye Contact Lens. 2003. PMID: 14555900
-
Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms?Cont Lens Anterior Eye. 2018 Feb;41(1):60-68. doi: 10.1016/j.clae.2017.07.007. Epub 2017 Aug 12. Cont Lens Anterior Eye. 2018. PMID: 28811095 Clinical Trial.
-
Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review.Arq Bras Oftalmol. 2019 Sep 9;82(5):436-445. doi: 10.5935/0004-2749.20190097. Arq Bras Oftalmol. 2019. PMID: 31508669
Cited by
-
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease.Drugs. 2022 Sep;82(14):1481-1488. doi: 10.1007/s40265-022-01782-4. Epub 2022 Oct 5. Drugs. 2022. PMID: 36197638 Free PMC article. Review.
-
A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations.Int J Mol Sci. 2023 Feb 1;24(3):2758. doi: 10.3390/ijms24032758. Int J Mol Sci. 2023. PMID: 36769079 Free PMC article. Review.
-
Considerations for Polymers Used in Ocular Drug Delivery.Front Med (Lausanne). 2022 Jan 28;8:787644. doi: 10.3389/fmed.2021.787644. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35155469 Free PMC article. Review.
-
Insight into the Lubrication and Adhesion Properties of Hyaluronan for Ocular Drug Delivery.Biomolecules. 2021 Sep 30;11(10):1431. doi: 10.3390/biom11101431. Biomolecules. 2021. PMID: 34680064 Free PMC article.
-
Combination Therapy with Trehalose and Hyaluronic Acid Restores Tear Lipid Layer Functionality by Ameliorating Inflammatory Response Protein Markers on the Ocular Surface of Dry Eye Patients.J Clin Med. 2025 Aug 5;14(15):5525. doi: 10.3390/jcm14155525. J Clin Med. 2025. PMID: 40807147 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources